Biontech Se Stock Performance
| BNTX Stock | USD 107.95 0.96 0.90% |
On a scale of 0 to 100, BioNTech holds a performance score of 7. The firm shows a Beta (market volatility) of 1.33, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioNTech will likely underperform. Please check BioNTech's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to make a quick decision on whether BioNTech's price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BioNTech SE are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, BioNTech showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.9 | Five Day Return 1.48 | Year To Date Return 11.65 | Ten Year Return 658.08 | All Time Return 658.08 |
Dividend Date 2022-06-17 | Ex Dividend Date 2022-06-02 |
1 | Moderna Sounds the Alarm Is China About to Seize the Biotech Crown from the U.S. | 12/11/2025 |
2 | BioNTech Is Up 5.1 percent After 90-Effective COVID Data Raises New Franchise Questions | 01/08/2026 |
3 | BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference | 01/12/2026 |
4 | BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and 17B Cash Plan | 01/14/2026 |
5 | BioNTech ernennt Kylie Jimenez zur neuen Personalvorstndin | 01/28/2026 |
6 | Goldman Sachs Highlights BioNTechs Immuno-Oncology and ADC Pipeline | 01/30/2026 |
7 | BioNTech SE Gets a Buy from Morgan Stanley - The Globe and Mail | 02/03/2026 |
8 | BioNTech SE Just Flipped The Script Is BNTX The Next Big Must-Cop or a Total Trap - AD HOC NEWS | 02/11/2026 |
| Begin Period Cash Flow | 11.7 B | |
| Total Cashflows From Investing Activities | -2.1 B |
BioNTech Relative Risk vs. Return Landscape
If you would invest 9,559 in BioNTech SE on November 21, 2025 and sell it today you would earn a total of 1,236 from holding BioNTech SE or generate 12.93% return on investment over 90 days. BioNTech SE is currently generating 0.2357% in daily expected returns and assumes 2.4743% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than BioNTech, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioNTech Target Price Odds to finish over Current Price
The tendency of BioNTech Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 107.95 | 90 days | 107.95 | about 24.06 |
Based on a normal probability distribution, the odds of BioNTech to move above the current price in 90 days from now is about 24.06 (This BioNTech SE probability density function shows the probability of BioNTech Stock to fall within a particular range of prices over 90 days) .
BioNTech Price Density |
| Price |
Predictive Modules for BioNTech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioNTech SE. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BioNTech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
BioNTech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BioNTech is not an exception. The market had few large corrections towards the BioNTech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BioNTech SE, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioNTech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.08 | |
β | Beta against Dow Jones | 1.33 | |
σ | Overall volatility | 7.75 | |
Ir | Information ratio | -0.03 |
BioNTech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioNTech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioNTech SE can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 2.75 B. Net Loss for the year was (677.7 M) with profit before overhead, payroll, taxes, and interest of 2.6 B. | |
| About 57.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: BioNTech SE Just Flipped The Script Is BNTX The Next Big Must-Cop or a Total Trap - AD HOC NEWS |
BioNTech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BioNTech Stock often depends not only on the future outlook of the current and potential BioNTech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioNTech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 240.4 M | |
| Cash And Short Term Investments | 16.8 B |
BioNTech Fundamentals Growth
BioNTech Stock prices reflect investors' perceptions of the future prospects and financial health of BioNTech, and BioNTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioNTech Stock performance.
| Return On Equity | -0.0304 | ||||
| Return On Asset | -0.023 | ||||
| Profit Margin | (0.18) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 9.63 B | ||||
| Shares Outstanding | 250.93 M | ||||
| Price To Earning | 5.19 X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 8.52 X | ||||
| Revenue | 2.75 B | ||||
| Gross Profit | 2.6 B | ||||
| EBITDA | (367.1 M) | ||||
| Net Income | (677.7 M) | ||||
| Cash And Equivalents | 9.33 B | ||||
| Cash Per Share | 38.30 X | ||||
| Total Debt | 254.2 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 91.19 X | ||||
| Cash Flow From Operations | 207.7 M | ||||
| Earnings Per Share | (2.84) X | ||||
| Market Capitalization | 26.85 B | ||||
| Total Asset | 22.53 B | ||||
| Retained Earnings | 19.1 B | ||||
| Working Capital | 16.28 B | ||||
| Current Asset | 284.67 M | ||||
| Current Liabilities | 143.37 M | ||||
About BioNTech Performance
Evaluating BioNTech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioNTech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioNTech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 171.97 | 180.57 | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.06) | (0.06) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.04) | (0.04) |
Things to note about BioNTech SE performance evaluation
Checking the ongoing alerts about BioNTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioNTech SE help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 2.75 B. Net Loss for the year was (677.7 M) with profit before overhead, payroll, taxes, and interest of 2.6 B. | |
| About 57.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: BioNTech SE Just Flipped The Script Is BNTX The Next Big Must-Cop or a Total Trap - AD HOC NEWS |
- Analyzing BioNTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioNTech's stock is overvalued or undervalued compared to its peers.
- Examining BioNTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioNTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioNTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioNTech's stock. These opinions can provide insight into BioNTech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.